- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Interventions
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 1,113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 21
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 11
- States / cities
- Glendale, Arizona • Covina, California • El Cajon, California + 7 more
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 78
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
- Conditions
- Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
- Interventions
- Relatlimab + Nivolumab, Nivolumab, Paclitaxel, Ramucirumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 20
- States / cities
- Daphne, Alabama • Bakersfield, California • Fullerton, California + 17 more
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer
- Interventions
- Niraparib
- Drug
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 80
- States / cities
- Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
- Procedure · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 883
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- zolbetuximab, nab-paclitaxel, gemcitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 25
- States / cities
- Fullerton, California • Whittier, California • Meriden, Connecticut + 22 more
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Glatiramer acetate (GA), Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 32 more
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Placebo, LY3202626
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 47 more
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 680
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
- Conditions
- Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
- Interventions
- Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 32
- States / cities
- Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
- Conditions
- COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
- Interventions
- Roflumilast, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 217
- States / cities
- Anniston, Alabama • Athens, Alabama • Florence, Alabama + 175 more
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- Tanezumab, placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 390
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more
- Conditions
- Psoriasis
- Interventions
- IDP-118 Vehicle Lotion, IDP-118 Vehicle Cream, IDP-118 Lotion, Ultravate Cream
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 14
- States / cities
- Fullerton, California • La Mesa, California • San Diego, California + 10 more
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
- Interventions
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 872
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more
- Conditions
- Migraine
- Interventions
- Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 28
- States / cities
- Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- Faster-acting insulin aspart, insulin detemir, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 116
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 87 more
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
- Interventions
- TORL-1-23, Pegfilgrastim (drug)
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 26
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more
- Conditions
- Essential Tremor
- Interventions
- SAGE-324, SAGE-324 Matched Placebo
- Drug
- Lead sponsor
- Sage Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Hoover, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
- Conditions
- Sjogren Syndrome
- Interventions
- VAY736, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 23
- States / cities
- Fullerton, California • La Palma, California • Brandon, Florida + 19 more
- Conditions
- Lung Cancer
- Interventions
- lobectomy, segmentectomy or wedge resection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 373
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CZP), Placebo
- Drug · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 101
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more